(Q37967467)

26 August 2017

title

Resistance-associated variants in chronic hepatitis C patients treated with protease inhibitors (English)

1 reference

26 August 2017

1 reference

1 reference

Maya Gambarin-Gelwan

1

1 reference

26 August 2017

Ira M Jacobson

series ordinal

2

1 reference

26 August 2017

language of work or name

1 reference

1 February 2012

1 reference

Current gastroenterology reports

26 August 2017

published in

1 reference

26 August 2017

volume

14

1 reference

26 August 2017

issue

1

1 reference

26 August 2017

page(s)

47-54

1 reference

https://scigraph.springernature.com/pub.10.1007/s11894-011-0237-1

26 August 2017

exact match

0 references

cites work

Boceprevir for untreated chronic HCV genotype 1 infection

1 reference

https://api.crossref.org/works/10.1007%2FS11894-011-0237-1

Telaprevir for previously untreated chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-011-0237-1

Boceprevir for previously treated chronic HCV genotype 1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-011-0237-1

Telaprevir for retreatment of HCV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-011-0237-1

Replication of hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-011-0237-1

Rates of evolutionary change in viruses: patterns and determinants

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-011-0237-1

Hepatitis C virus genetic variability: pathogenic and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-011-0237-1

Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-011-0237-1

Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-011-0237-1

A target on the move: innate and adaptive immune escape strategies of hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-011-0237-1

Phenotypic Characterization of Resistant Val36 Variants of Hepatitis C Virus NS3-4A Serine Protease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-011-0237-1

Molecular basis of telaprevir resistance due to V36 and T54 mutations in the NS3-4A protease of the hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-011-0237-1

Phenotypic and structural analyses of hepatitis C virus NS3 protease Arg155 variants: sensitivity to telaprevir (VX-950) and interferon alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-011-0237-1

Drug resistance against HCV NS3/4A inhibitors is defined by the balance of substrate recognition versus inhibitor binding

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-011-0237-1

Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-011-0237-1

Antiviral resistance and specifically targeted therapy for HCV (STAT-C).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-011-0237-1

Mutations conferring resistance to SCH6, a novel hepatitis C virus NS3/4A protease inhibitor. Reduced RNA replication fitness and partial rescue by second-site mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-011-0237-1

Identification and analysis of fitness of resistance mutations against the HCV protease inhibitor SCH 503034.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-011-0237-1

Selection and Characterization of Hepatitis C Virus Replicons Dually Resistant to the Polymerase and Protease Inhibitors HCV-796 and Boceprevir (SCH 503034)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-011-0237-1

Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-011-0237-1

Telaprevir and peginterferon with or without ribavirin for chronic HCV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-011-0237-1

Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-011-0237-1

A multi-variant, viral dynamic model of genotype 1 HCV to assess the in vivo evolution of protease-inhibitor resistant variants

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-011-0237-1

Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-011-0237-1

Tracking the evolution of multiple in vitro hepatitis C virus replicon variants under protease inhibitor selection pressure by 454 deep sequencing

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-011-0237-1

Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naïve patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-011-0237-1

Natural prevalence of hepatitis C virus variants with decreased sensitivity to NS3.4A protease inhibitors in treatment-naive subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-011-0237-1

GT-1a or GT-1b Subtype-Specific Resistance Profiles for Hepatitis C Virus Inhibitors Telaprevir and HCV-796

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-011-0237-1

Replication of hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-011-0237-1

Treatment failure and resistance with direct-acting antiviral drugs against hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-011-0237-1

Characterization of resistance mutations against HCV ketoamide protease inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-011-0237-1

Role of minority populations of human immunodeficiency virus type 1 in the evolution of viral resistance to protease inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-011-0237-1

Relative Replication Capacity and Selective Advantage Profiles of Protease Inhibitor-Resistant Hepatitis C Virus (HCV) NS3 Protease Mutants in the HCV Genotype 1b Replicon System

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-011-0237-1

Telaprevir for previously treated chronic HCV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-011-0237-1

Resistance profiling of hepatitis C virus protease inhibitors using full-length NS3.

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22161022

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Scientific rationale for antiretroviral therapy in 2005: viral reservoirs and resistance evolution.

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22161022

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

1 reference

https://pubmed.ncbi.nlm.nih.gov/22161022

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S11894-011-0237-1

1 reference

26 August 2017

1 reference